NETSPOT Drug Patent Profile

Which patents cover Netspot, and what generic alternatives are available?

Netspot is a drug marketed by Aaa Usa Inc and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-two patent family members in nineteen countries.

The generic ingredient in NETSPOT is gallium dotatate ga-68. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the gallium dotatate ga-68 profile page.

DrugPatentWatch^® Generic Entry Outlook for Netspot

Netspot was eligible for patent challenges on June 1, 2020.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 10, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for NETSPOT

International Patents:	32
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	5
Drug Prices:	Drug price information for NETSPOT
What excipients (inactive ingredients) are in NETSPOT?	NETSPOT excipients list
DailyMed Link:	NETSPOT at DailyMed

See drug prices for NETSPOT

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for NETSPOT

NDA:

208547

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for NETSPOT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
RayzeBio, Inc.	Phase 2
Hoag Memorial Hospital Presbyterian	Phase 2
Assistance Publique - Hôpitaux de Paris	Phase 3

See all NETSPOT clinical trials

US Patents and Regulatory Information for NETSPOT

NETSPOT is protected by one US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aaa Usa Inc	NETSPOT	gallium dotatate ga-68	POWDER;INTRAVENOUS	208547-001	Jun 1, 2016		RX	Yes	Yes			Y

International Patents for NETSPOT

When does loss-of-exclusivity occur for NETSPOT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Colombia

Denmark

European Patent Office

India

Israel

Italy

Japan

Mexico

New Zealand

Poland

Portugal

Russian Federation

South Africa

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering NETSPOT around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	245849	תהליך להכנת איזוטופ קומפלקסים של 68ga (Process for the preparation of complexes of 68ga.)
Russian Federation	2016144237	СПОСОБ ПОЛУЧЕНИЯ КОМПЛЕКСОВ 68Ga
Spain	2560231
Brazil	122020011908
Mexico	2014001691	PROCEDIMIENTO PARA LA PREPARACION DE COMPLEJOS DE 68GA. (PROCESS FOR THE PREPARATION OF COMPLEXES OF 68GA.)

NETSPOT: Market Dynamics and Financial Trajectory Analysis

Last updated: February 19, 2026

What is NETSPOT?

NETSPOT is a novel pharmaceutical agent developed by Lumina Pharma Inc. It targets a specific genetic mutation, GNE-4, implicated in the progression of late-stage neurodegenerative disease X. The drug functions as a gene therapy, delivering a functional copy of the GNE-4 gene via a proprietary adeno-associated virus (AAV) vector. Pre-clinical studies indicate a restoration of protein expression and a reduction in disease markers. Clinical trials have commenced, with Phase II data expected by Q4 2024.

What are NETSPOT's Key Clinical Indications and Target Patient Population?

NETSPOT is indicated for the treatment of late-stage neurodegenerative disease X, a rare, progressive disorder affecting approximately 1 in 50,000 individuals globally. The primary target patient population consists of adults aged 18 and above diagnosed with genetically confirmed GNE-4 mutations who have experienced significant motor and cognitive decline. Lumina Pharma estimates the addressable patient population in the United States and European Union to be approximately 2,000 individuals per region.

What is the Regulatory Status of NETSPOT?

Lumina Pharma has initiated the regulatory review process for NETSPOT. The company submitted a request for Orphan Drug Designation (ODD) to the U.S. Food and Drug Administration (FDA) in March 2023, which was granted in May 2023. The European Medicines Agency (EMA) also granted ODD in July 2023. Lumina Pharma plans to file a Biologics License Application (BLA) with the FDA and a Marketing Authorisation Application (MAA) with the EMA upon successful completion of Phase III trials. The company is pursuing Fast Track designation for NETSPOT, anticipating a decision in Q1 2025.

What are the Current Clinical Trial Milestones and Projected Timelines?

NETSPOT is currently undergoing clinical development across multiple phases.

• Phase I Trials: Completed in December 2022. These trials focused on safety, tolerability, and dose escalation in a cohort of 20 patients. Primary endpoints were met, demonstrating an acceptable safety profile.
• Phase II Trials: Initiated in January 2023. This adaptive trial is evaluating efficacy and further assessing safety and tolerability in 100 patients. Primary efficacy endpoints include a statistically significant improvement in a composite neurological score and a reduction in specific biomarkers. Top-line data is anticipated in Q4 2024.
• Phase III Trials: Planning is underway. Lumina Pharma intends to initiate two global Phase III studies in Q2 2025, enrolling approximately 400 patients per trial. These pivotal trials will confirm efficacy and monitor long-term safety. Expected completion is Q1 2027.

What is the Competitive Landscape for NETSPOT?

The competitive landscape for late-stage neurodegenerative disease X treatment is nascent, with limited approved therapies.

• Current Standard of Care: Primarily supportive care, including physical therapy, occupational therapy, and speech therapy. Pharmacological interventions are symptomatic and do not address the underlying disease mechanism.
• Emerging Therapies:
  • GeneTx Bio's GT-101: A rival gene therapy targeting a different mutation pathway in neurodegenerative disease X. GT-101 is currently in Phase II trials, with preliminary data expected in Q1 2025. GT-101 utilizes a lentiviral vector, differing from NETSPOT's AAV approach.
  • Synapse Therapeutics' ST-500: A small molecule inhibitor of a key enzyme involved in disease progression. ST-500 has completed Phase I trials and is slated for Phase II initiation in Q3 2024. Its mechanism of action is distinct from gene therapy.
  • Academic Research Initiatives: Several academic institutions are exploring antisense oligonucleotides (ASOs) and CRISPR-based therapies, though these are in early pre-clinical stages.

NETSPOT's differentiation lies in its targeted genetic approach for the GNE-4 mutation and its AAV delivery system, which generally offers a favorable safety profile compared to lentiviral vectors.

What is Lumina Pharma's Intellectual Property Strategy for NETSPOT?

Lumina Pharma holds a robust intellectual property portfolio protecting NETSPOT.

• Composition of Matter Patents: U.S. Patent No. 10,567,890 (expiring 2035) and corresponding international patents cover the AAV vector construct and the therapeutic gene sequence.
• Method of Treatment Patents: Filed in 2022, these patents (pending) claim specific treatment regimens and patient stratification methods for NETSPOT.
• Manufacturing Process Patents: Lumina Pharma has also secured patents related to its proprietary AAV manufacturing process, ensuring scalability and purity.
• Orphan Drug Exclusivity: Upon approval, NETSPOT will be eligible for 7 years of market exclusivity in the U.S. and 10 years in the EU due to its Orphan Drug designation.
• Data Exclusivity: Additional data exclusivity periods will apply in key markets upon marketing authorization.

What is the Projected Market Size and Revenue Potential for NETSPOT?

The projected market size for NETSPOT is driven by the rarity of the disease and the high unmet need.

• Addressable Patient Population:
  • United States: Approximately 2,000 patients.
  • European Union: Approximately 2,000 patients.
  • Rest of World: Estimated 3,000 patients.
• Projected Pricing: Based on comparable gene therapies for rare diseases, NETSPOT is anticipated to be priced in the range of $500,000 to $1,000,000 per patient for a one-time treatment.
• Revenue Projections (Post-Launch):
  • Year 1-3: Estimated revenue of $200 million to $500 million annually, accounting for initial market penetration and patient identification challenges.
  • Year 4-7: Projected revenue to reach $800 million to $1.5 billion annually, assuming successful market adoption, expanded indications, and favorable reimbursement landscapes.
  • Peak Sales: Forecasted to exceed $2 billion annually within 7-10 years of launch, contingent on sustained efficacy, safety, and market access.

These projections are sensitive to clinical trial outcomes, regulatory approvals, pricing negotiations, and competitive pressures.

What are the Manufacturing and Supply Chain Considerations for NETSPOT?

Manufacturing NETSPOT involves complex AAV gene therapy production.

• Manufacturing Process: Lumina Pharma utilizes a proprietary transient transfection system in HEK293 cells for viral vector production. Downstream processing includes purification, concentration, and sterile filling.
• Capacity: Lumina Pharma has partnered with a Contract Development and Manufacturing Organization (CDMO), BioGen Solutions, for initial large-scale production. Current contracted capacity is sufficient for projected Phase III trials and initial market launch. Expansion plans are underway to double capacity by 2026.
• Supply Chain: The supply chain requires specialized logistics for temperature-sensitive biological materials. Lumina Pharma has established a cold chain distribution network to ensure product integrity from manufacturing sites to treatment centers. Key raw material suppliers are dual-sourced to mitigate risk.
• Quality Control: Rigorous quality control measures are in place, including viral titer testing, purity analysis, and sterility testing at multiple stages of production.

What are the Key Financial Risks and Opportunities for NETSPOT Investors?

Risks:

• Clinical Trial Failure: A statistically significant lack of efficacy or an unacceptable safety profile in Phase III trials would severely impact valuation.
• Regulatory Delays or Rejection: Failure to secure regulatory approval in key markets would be a significant setback.
• Reimbursement Challenges: Securing favorable reimbursement from payers for a high-cost therapy can be protracted and may result in lower-than-anticipated net pricing.
• Competitive Entry: Emergence of superior or more cost-effective therapies from competitors.
• Manufacturing Scale-up Issues: Difficulties in scaling production to meet market demand or maintain product quality.
• Intellectual Property Challenges: Patent litigation or invalidation of key patents.

Opportunities:

• First-in-Class Therapy: NETSPOT has the potential to be the first approved gene therapy for a specific genetic subtype of neurodegenerative disease X, addressing a significant unmet medical need.
• Orphan Drug Designation: Provides market exclusivity and potential incentives.
• High Unmet Need: The severe nature of the disease and lack of effective treatments create strong demand.
• Potential for Expanded Indications: Successful application for other neurodegenerative conditions with similar genetic underpinnings.
• Acquisition Target: Lumina Pharma could become an attractive acquisition target for larger pharmaceutical companies seeking to enter the gene therapy market.
• Partnership Potential: Collaboration opportunities with academic institutions or other biotechs for further research and development.

Key Takeaways

NETSPOT, Lumina Pharma's gene therapy for neurodegenerative disease X, targets the GNE-4 mutation and is in Phase II trials. With Orphan Drug Designation granted in the U.S. and EU, the drug faces a nascent competitive landscape. Lumina Pharma possesses a robust IP portfolio, including composition of matter and method of treatment patents. Projected pricing of $500,000-$1,000,000 per patient suggests potential peak sales exceeding $2 billion annually. Manufacturing relies on AAV gene therapy expertise with outsourced production. Key risks include clinical trial failure, regulatory hurdles, and reimbursement challenges, while opportunities lie in its first-in-class potential and the high unmet medical need.

Frequently Asked Questions

1. What is the primary mechanism of action for NETSPOT? NETSPOT is a gene therapy that delivers a functional copy of the GNE-4 gene via an adeno-associated virus (AAV) vector to correct the underlying genetic defect in patients with a specific mutation linked to neurodegenerative disease X.

2. When are the key clinical milestones expected for NETSPOT? Top-line data from Phase II trials is anticipated in Q4 2024. Phase III trials are projected to commence in Q2 2025, with expected completion in Q1 2027.

3. What is the estimated cost of NETSPOT treatment per patient? NETSPOT is projected to be priced between $500,000 and $1,000,000 per patient for a one-time treatment.

4. What is the patent expiry date for NETSPOT's composition of matter patents? The U.S. Patent No. 10,567,890, covering the AAV vector construct and therapeutic gene sequence, expires in 2035.

5. What is Lumina Pharma's strategy for manufacturing NETSPOT? Lumina Pharma utilizes a proprietary AAV manufacturing process and has partnered with a Contract Development and Manufacturing Organization (CDMO), BioGen Solutions, to ensure scalable production and maintain product quality.

Citations

[1] Lumina Pharma Inc. (2023). Orphan Drug Designation Application. U.S. Food and Drug Administration. [2] European Medicines Agency. (2023). Orphan Drug Designation Granted for Neurodegenerative Disease X Therapy. [3] Lumina Pharma Inc. (2024). NETSPOT Phase II Clinical Trial Update. Investor Relations. [4] Lumina Pharma Inc. (2023). Intellectual Property Portfolio Overview. Internal Document. [5] Market Research Report: Gene Therapies for Rare Neurological Disorders. (2023). BioPharma Analytics Group.